FutuRx Portfolio

A2i Therapeutics Ltd. is a joint venture of FutuRx and Atomwise, designed to utilize Atomwise’s AI platform, AtomNet® technology, to target ADAR1, a key protein involved in controlling the innate immune response, neurological disorders, metabolic diseases and potentially a key target for immuno-oncology and neurological homeostasis. Scientific Approach A2i Therapeutics is developing small molecule inhibitors […]
Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. Bsense is pioneering a novel approach targeting multiple pain-related mechanisms using a single compound, to achieve greater efficacy and safety.
CDO: Dr. Tal Hasson CatchMe Therapeutics develops a novel class of precision medicines that targets the epitranscriptome machinery. The emerging field of RNA epitranscriptomics refers to a set of RNA modifying proteins and modified-RNA binding proteins that control different aspects of RNA biology and holds great potential for new cancer therapeutics. Scientific Background During the […]
Circuit-Bio is a synthetic biology company developing an innovative unique platform of logical gene circuits for cancer immunotherapy. The Company’s platform focuses on generating gene circuits able to locally and accurately produce a combination of multiple immune-stimulating proteins (immunomodulators) exclusively expressed in targeted tumor cells. Thus, the circuit selectively converts cancer cells into ‘Trojan horses’ utilize […]
Epeius pharma is a cell and gene therapy company developing next generation biological vehicles for delivery of therapeutic proteins into the central nervous system (CNS). Efficient and predictable therapeutics delivery is particularly challenging in neurological diseases due to the blood-brain barrier (BBB), which tightly regulates the transport of molecules to the brain, and blocks the […]
Scientific Approach ReadeRx is developing small molecule inhibitors targeting the RNA binding protein IGF2BP1 as a novel treatment for cancer. IGF2BP1 is an oncofetal RNA binding protein expressed in many types of cancers. it regulates RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. IGFB2P1 is widely expressed in development […]
RNAble is a preclinical biotechnology company developing a potent small-molecule inhibitor targeting FTO, a key driver of oncogenic RNA biology. Mechanistic studies have led to the identification of a specific biomarker that predicts pan-cancer sensitivity to the inhibitor across both hematological and solid malignancies. RNAble’s lead candidate has demonstrated superior anti-tumor activity compared to standard […]
Selene Therapeutics is pioneering a new therapeutic strategy for treating refractory epilepsy – regulation of the neuronal activity set point by reduction of the neuronal mean firing rate (MFR). Selene aims to develop small molecule for inhibitors of Dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme located on the inner mitochondrial membrane and participating in several key […]
Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases by applying a novel, proprietary, computational engine to directly identify patient cohorts and determine therapeutic designs. Skip’s website: www.skiptx.com SCIENTIFIC BACKGROUND Thousands of rare genetic disorders affect millions of people worldwide, however the small number of patients for each disease, further segregated by patient-specific mutations, […]

Incubator Graduates

Discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and topical diseases that stem from dysbiosis.
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy.
Pi Therapeutics is a preclinical-stage pharmaceutical company a first-in-class small molecule cancer drug
Protekt Therapeutics is a biopharmaceutical company aiming to develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment (MCI)